BAX and lip and oral cavity carcinoma: The current study offers in vitro experimental studies on a human cell line model evidence of the therapeutic impact of hesperidin on inhibiting oral cancer cells by inhibiting pro-inflammatory signaling molecules and activating BAX (pro-apoptotic protein) signaling.